JRS PHARMA is pleased to announce that the JRS Pharma site in Weißenborn, Germany was awarded an EXCiPACT Certificate from DQS for the production of Microcrystalline Cellulose and Silicified Microcrystalline Cellulose as well as Good Distribution Practice for the central logistic warehouse.
JRS PHARMA is pleased to announce that the JRS Pharma & Gujarat Microwax Private Limited sites producing Microcrystalline Cellulose and Superdisintegrants were awarded an EXCiPACT Certificate from SGS.
Tokyo, Japan – March 29th, 2018 - JRS PHARMA is pleased to announce that PROSOLV® SMCC (Silicified Microcrystalline Cellulose) is now monographed with the Japanese Pharmaceutical Excipients (JPE), joining the rest of JRS PHARMA’s complete portfolio of excipients solutions available in Japan.
JRS PHARMA has announced the upcoming grand opening of a new laboratory located at their Diadema, Brazil location. The lab is scheduled to be opened during JRS PHARMA’s Latin America Technical Seminar on June 26-27, 2017.
JRS PHARMA has announced the worldwide release of the Povidone Family product line, the latest addition to their excipients portfolio. This product line consists of three products: VIVAPHARM® PVP (Povidone), VIVAPHARM® PVP/VA 64 (Copovidone), and VIVAPHARM® PVPP (Crospovidone).
JRS PHARMA products can now be purchased direct in India. All business has been transferred from S. Zhaveri Pharmakem Pvt. Ltd. to Rettenmaier India Pvt. Ltd., a wholly owned subsidiary of the JRS Group ( J. RETTENMAIER & Söhne)
JRS PHARMA, headquartered in Germany, has entered into a joint venture agreement with SSP, headquartered in Chongqing, China, for the commercialization of povidone products. The new JV company is Star-Tech & JRS Specialty Products.